Roivant raised USD 200 million, now valued at USD 7 billion
The Basel-based pharmaceutical company Roivant Sciences has raised USD 200 million in a funding round. As a result, the company is now valued at an estimated USD 7 billion.
Vivek Ramaswamy, Founder and Chief Executive Officer of Roivant Sciences
Roivant Sciences reported in a press release that all existing institutional shareholders participated in the latest funding round. The Basel pharma company also attracted a number of new investors, including NovaQuest Capital Management and RTW Investments. These new investors made up the majority of this latest funding drive, in which Roivant raised USD 200 million. The round has not yet finished and is only expected to close in early December. According to the press release, this latest financing puts the value of Roivant Sciences at approximately USD 7 billion.
Since the previous Roivant funding round last year, the number of therapies in development has grown from 14 to 34 and the company has increased its subsidiary “Vants” from six to 14. There has also been growth in employee numbers across Roivant and the Vants, from under 350 to more than 750. In addition, the Roivant subsidiary Enzyvant initiated a biologics licence application for a regenerative therapy to the U.S. Food and Drug Administration (FDA).
For 2019, the company anticipates topline data from six Phase 3 clinical trials. Roivant Health also intends to launch new Vants next year. This subsidiary was founded in June to develop companies that bring innovative medicines to emerging markets and improve the process of developing and commercialising new medicines through the application of technology. Sales are also expected to grow for Datavant, founded in autumn 2017 as a subsidiary that uses artificial intelligence in data analysis to improve the clinical trial process and accelerate drug development.
Roivant Sciences and its subsidiaries are supported by BaselArea.swiss as they establish themselves in Basel.
Share this article
You might also be interested in
Moderna is opening a location in Basel and is advancing the production of the coronavirus vaccine from there. The Swiss government has just signed a supply contract with the US company for 4.5 million doses of the vaccine.Read More
The Japanese conglomerate Yokogawa has established a Swiss subsidiary based at the Switzerland Innovation Park Basel Area. Here, the focus will be on driving forward innovation in the field of biotechnology.Read More
The Werner Siemens Foundation is to invest an additional 12 million Swiss francs in the Miracle project. Researchers at the University of Basel are developing visionary technology for the use of robots in surgery within the framework of this project.Read More
The Basel-based biopharmaceutical company Versameb has successfully closed a seed financing round. Versameb develops therapies on the basis of mRNA sequences and is now seeking to drive forward the clinical development of its platform devised for this.Read More
Two thirds of the value added attributable to the pharmaceutical industry as a whole in Switzerland is generated in the Basel Area, as revealed by an Interpharma report. However, the region also shines in an international comparison. Interpharma CEO René Buholzer regards it as “probably the most productive life sciences location in the world”.Read More
Resistell AG, based in Muttenz in the canton of Basel-Landschaft, has received a grant of up to 2.5 million euros and additional equity capital financing from a European fund with the aim of accelerating innovation. The company is developing the world’s fastest test against antibiotic resistance.Read More